EP2568811A4 - TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER - Google Patents

TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER

Info

Publication number
EP2568811A4
EP2568811A4 EP10851531.3A EP10851531A EP2568811A4 EP 2568811 A4 EP2568811 A4 EP 2568811A4 EP 10851531 A EP10851531 A EP 10851531A EP 2568811 A4 EP2568811 A4 EP 2568811A4
Authority
EP
European Patent Office
Prior art keywords
mci
alzheimer
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10851531.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2568811A1 (en
Inventor
Mark Lovell
Bert Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/en
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of EP2568811A1 publication Critical patent/EP2568811A1/en
Publication of EP2568811A4 publication Critical patent/EP2568811A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10851531.3A 2010-05-13 2010-11-18 TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER Withdrawn EP2568811A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease
PCT/US2010/057287 WO2011142778A1 (en) 2010-05-13 2010-11-18 Treatment of mci and alzheimer's disease

Publications (2)

Publication Number Publication Date
EP2568811A1 EP2568811A1 (en) 2013-03-20
EP2568811A4 true EP2568811A4 (en) 2014-03-12

Family

ID=44923820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10851531.3A Withdrawn EP2568811A4 (en) 2010-05-13 2010-11-18 TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER

Country Status (6)

Country Link
EP (1) EP2568811A4 (enExample)
JP (1) JP2013526518A (enExample)
CN (1) CN102984938A (enExample)
AU (1) AU2010353287A1 (enExample)
CA (1) CA2799162A1 (enExample)
WO (1) WO2011142778A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2994160T (pt) * 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
KR101850827B1 (ko) 2013-06-28 2018-05-31 가부시키가이샤 엠씨비아이 인지기능장애질환의 바이오 마커 및 당해 바이오 마커를 사용하는 인지기능장애질환의 검출방법
EA028587B1 (ru) * 2014-01-29 2017-12-29 Бристол-Майерс Сквибб Компани Ариллактамные ингибиторы киназы
CN106177046A (zh) * 2016-08-29 2016-12-07 杨添福 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法
CN106645505A (zh) * 2016-11-18 2017-05-10 中国医科大学 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN106636388A (zh) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
US20220064214A1 (en) * 2019-01-07 2022-03-03 Cenna Biosciences Inc. Novel peptides and uses thereof
JP7321017B2 (ja) * 2019-07-17 2023-08-04 東海物産株式会社 機能性食品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028761A1 (en) * 1999-08-16 2002-03-07 Koppel Gary A. Neurotherapeutic use of carboxypeptidase inhibitors
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010108052A2 (en) * 2009-03-20 2010-09-23 H. Lundbeck A/S Amide derivatives as neuropeptide y5 receptor ligands

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002A (en) * 1851-03-25 Upright pianoforte
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
EP1069918A4 (en) * 1998-04-08 2002-02-20 Univ Oregon Health Sciences ACTIVATION OF GALLIUM CELL FIXATION
JP2004513965A (ja) * 2000-11-21 2004-05-13 ジク、ハワード １，４−ジヒドロピリジンカルシウムチャンネルブロッカーを利用するヘルペス神経系ウイルス症状のための療法
JP2007512339A (ja) * 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション 記憶障害の処置における（＋）−イソプロピル２−メトキシエチル４−（２−クロロ−３−シアノ−フェニル）−１，４−ジヒドロ−２，６−ジメチル−ピリジン−３，５−ジカルボキシラートの使用
PT1874311E (pt) * 2005-04-15 2011-11-25 Res & Innovation S P A Método para prevenir, retardar ou reverter a deposição anómala de amilóide
US20090286879A1 (en) * 2005-12-02 2009-11-19 Kiyoshi Hashizume Preventive or Therapeutic Drug for Alzheimer-Type Dementia
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
CA2648243C (en) * 2006-04-11 2015-12-22 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20080293712A1 (en) * 2007-03-05 2008-11-27 Wyeth Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028761A1 (en) * 1999-08-16 2002-03-07 Koppel Gary A. Neurotherapeutic use of carboxypeptidase inhibitors
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010108052A2 (en) * 2009-03-20 2010-09-23 H. Lundbeck A/S Amide derivatives as neuropeptide y5 receptor ligands

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DONG H. KIM: "Rearrangements of 4-(2-Aminophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 23, no. 5, 1 September 1986 (1986-09-01), US, pages 1471 - 1474, XP055100273, ISSN: 0022-152X, DOI: 10.1002/jhet.5570230543 *
DONNA L SAVIGNI ET AL: "Iron and transition metal transport into erythrocytes mediated by nifedipine degradation products and related compounds", BIOCHEMICAL PHARMACOLOGY, vol. 65, no. 8, 1 April 2003 (2003-04-01), pages 1215 - 1226, XP055100193, ISSN: 0006-2952, DOI: 10.1016/S0006-2952(03)00045-5 *
GÖRLITZER K ET AL: "3,6-Diazaphenanthrene aus Nifedipin", ARCHIV DER PHARMAZIE, WILEY VERLAG, WEINHEIM, vol. 318, no. 2, 1 February 1985 (1985-02-01), pages 97 - 105, XP002668333, ISSN: 0365-6233 *
GÖRLITZER K ET AL: "9-Chlor-3,6-diazaphenanthrene aus Nifedipin", ARCHIV DER PHARMAZIE, WILEY VERLAG, WEINHEIM, vol. 318, no. 2, 1 January 1985 (1985-01-01), pages 106 - 110, XP002668334, ISSN: 0365-6233 *
KAMETANI T ET AL: "NITRENES. PART III. THE REACTION OF 4-(2-NITROPHENYL)PYRIDINE DERIVATIVES WITH TRIETHYL PHOSPHITE", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1969 (1969-01-01), pages 138 - 140, XP009004598, ISSN: 0022-4952, DOI: 10.1039/J39690000138 *
PETROW V A: "New Syntheses of Heterocyclic Compounds. Part VIII. The Schmidt Rearrangement of 1 : 3-Dimethyl-2-azafluorenones (continued)", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY, LETCHWORTH; GB, 1 January 1946 (1946-01-01), pages 888 - 891, XP002668516, ISSN: 0368-1769 *
See also references of WO2011142778A1 *

Also Published As

Publication number Publication date
CA2799162A1 (en) 2011-11-17
EP2568811A1 (en) 2013-03-20
JP2013526518A (ja) 2013-06-24
WO2011142778A1 (en) 2011-11-17
AU2010353287A1 (en) 2012-11-29
CN102984938A (zh) 2013-03-20

Similar Documents

Publication Publication Date Title
EP2429992A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
IL287794A (en) Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
IL217768A0 (en) Treatment of crohn's disease with laquinimod
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
PL2104682T3 (pl) Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
IL230441A0 (en) Diagnosis of Alzheimer's disease
GB2496801B (en) A method of treating alzheimer's disease
IL260078B (en) Therapy used to treat Gaucher disease
IL237730B (en) Treatment of mild and moderate Alzheimer's disease
EP2391379A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
PL2565184T3 (pl) Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera
EP2413696A4 (en) COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
HK1183408A (en) Treatment of mci and alzheimer's disease
EP2613849A4 (en) RADIATION THERAPY FOR THE TREATMENT OF MORBUS ALZHEIMER
GB201018362D0 (en) Treatment of dupuytren's disease
GB0811555D0 (en) Treatment of Alzheimer's disease
GB201101088D0 (en) L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease
GB201113718D0 (en) Treatment of Dupuytren's Disease
IL214340A0 (en) Methods and compositions for treating alzheimer's disease
GB201018325D0 (en) Treatment for dupuytren's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183408

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20140211

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/40 20060101AFI20140205BHEP

Ipc: A61P 25/28 20060101ALI20140205BHEP

Ipc: A61K 31/4375 20060101ALI20140205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1183408

Country of ref document: HK